First-in-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short-Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge
SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell-Mediated Diseases
Characterization of a Novel Oral Small Molecule PTH1R Agonist: Sustained Control of Serum Calcium and Modulation of Bone Biomarkers in TPTx Rats
Recent Comments